Finally, to evaluate the clinical relevance of c-MYC methylation by SMYD3, we assessed c-MYC K158/K163Me levels by immunohistochemistry in normal and cancer tissues from CRC patients with advanced-stage cancer. The gene discussed is SMYD3; the disease is cancer.